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Summary
Background: TNF-alpha is an important mediator in allergy also for its effects on eosinophils.
Methods: The effect of dexamethasone on TNF-alpha induced eosinophils survival, degranulation
(ECP), cytokines release (IL-8, GM-CSF) and adhesion to VCAM-1, ICAM-1 and IgG coated wells
(EPO release) were evaluated.
Results: The drug inhibited IL-8 and GM-CSF production, but not viability, degranulation or
adhesion in human peripheral blood eosinophils.
Conclusion: These results indicate that part of the activity of glucocorticosteroids on eosinophils
may be mediated by their ability to inhibit cytokine secretion that in turn is important for the
perpetuation of the allergic inflammation.
Background
Eosinophils are bone marrow-derived granulocytes that
play a crucial role in allergic inflammation. TNF-α  is a
pro-inflammatory cytokine synthesized by many inflam-
matory and structural cells. We previously demonstrated
that mast cell-derived TNF-α  induced eosinophil survival
by autocrine production of GM-CSF [1]. TNF-α  is also
involved in eosinophil adhesion to endothelial cells and
induces eosinophil activation, degranulation, and
cytokines production. Glucocorticosteroids (GCS), the
main anti-inflammatory drugs in allergic diseases, have
been demonstrated to decrease circulating and tissue eosi-
nophils. In vitro dexamethasone can inhibit eosinophil
survival [2], expression of adhesion molecules [3], and
cytokines production [4]. However, the effect of GCS on
TNF-α  induced eosinophil activation has only been par-
tially investigated. The present study evaluated the effect
of dexamethasone on TNF-α  induced eosinophil degran-
ulation, cytokines release and adhesion to VCAM-1,
ICAM-1 and IgG.
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Materials and Methods
Cells culture
Eosinophils were purified (>95%) from the peripheral
blood of healthy non-atopic volunteers as previously
described [5]. Freshly isolated eosinophils (viability
>98%) were cultured in 96 well flat bottom tissue culture
plates (Costar, High Wycombe, UK) (1.5 × 105/200 µl/
well) in RPMI-1640 supplemented with 10% heat inacti-
vated foetal calf serum (FCS) containing 2 mM L-
glutamine, 100 U/ml penicillin, and 100 µg/ml strepto-
mycin in the presence or absence of rhTNF-α  (0.01–100
ng/ml, R&D Systems, Abingdon, UK), or GM-CSF (10 ng/
ml, R&D Systems, Abingdon, UK) as a positive control
(37°C, 5% CO2). Dexamethasone (Glaxo-Wellcome-SKB,
Stevenage, UK) (1 µM) was added to the eosinophil cul-
tures together with TNF-α (50 ng/ml for degranulation
and 20 ng/ml for survival and cytokines release) or with
GM-CSF (10 ng/ml). After 22 hrs of culture in absence or
presence of dexamethasone (1 µM) eosinophil survival
was evaluated by Trypan blue exclusion test.
Eosinophils degranulation and cytokines release
ECP level was measured in the culture supernatants by a
RIA kit (ECP, Pharmacia Upjohn, Milton Keynes, UK).
GM-CSF and IL-8 content was detected in the culture
supernatants by ELISA kit (R&D Systems, Abingdon, UK).
Effect of TNF-α  on eosinophil viability in vitro Figure 1
Effect of TNF-α  on eosinophil viability in vitro. Eosinophils 
were incubated with different concentrations of TNF-α  for 
22 hrs. Eosinophil viability was evaluated by Trypan blue 
exclusion test. Values are expressed as percentage of survival 
increase in the presence of TNF-α  vs medium alone. Values 
are mean ± SEM (n = 14).
Effect of dexamethsone on TNF-α -induced ECP release from  eosinophils Figure 2
Effect of dexamethsone on TNF-α -induced ECP release from 
eosinophils. Eosinophils were cultured in medium alone (con-
trol) or with dexamethsone (medium+Dexa) or in the pres-
ence of TNF-α  alone (50 ng/ml) (TNF-α ) or TNF-α  with 
dexamethsone (1 µM) (TNF-α +Dexa). ECP release was eval-
uated by RIA. Values are mean ± SEM (n = 3).
Effect of TNF-α  on IL-8 release from eosinophils Figure 3
Effect of TNF-α  on IL-8 release from eosinophils. Eosinophils 
were cultured with different concentrations of TNF-α  (0 – 
100 ng/ml). IL-8 release was evaluated by ELISA. Values are 
mean ± SEM (n = 5).Clinical and Molecular Allergy 2005, 3:5 http://www.clinicalmolecularallergy.com/content/3/1/5
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Adhesion assay
Eosinophils (104/100 µl/well) were cultured in medium
alone or with TNF-α  (20 ng/ml) or GM-CSF (10 ng/ml) in
the presence or absence of dexamethasone (1 µM) (30
min, 37°C) in 96 well plates pre-coated with recombinant
VCAM-1, ICAM-1 or IgG. As a marker of adhesion EPO
was detected as previously described [5]. Results are
expressed as mean ± SEM.
Statistical analysis
Statistical analysis was performed by Student's t paired
test. A p  value of <0.05 was considered statistically
significant.
Results
TNF-α  significantly increased eosinophil viability in a
concentration-dependent fashion, compared to culture in
medium alone, with a maximal effect at 20 ng/ml (Figure
1). This effect was not influenced by the addition of dex-
amethasone in the culture medium (13.3% vs 11.5%).
Incubation of eosinophils with TNF-α  induced a signifi-
cant release of ECP compared to eosinophils cultured in
medium alone (24.5 ± 8.9 vs 6.9 ± 1.2 pg/106; p < 0.05).
However, addition of dexamethasone in the cultures did
not affect TNF-α -induced ECP release (Figure 2). The
release of IL-8 by TNF-α  treated eosinophils was dose-
dependently proportional to the concentrations of TNF-α .
A maximal release was achieved at 100 ng/ml (1770,49 ±
129 pg/ml; p < 0.05) (Figure 3). TNF-α  also induced GM-
CSF release by eosinophils although to a lesser extent than
that of IL-8 (data not shown). Treatment of the cultures
with dexamethasone completely blocked the TNF-α -
induced release of both IL-8 and GM-CSF (p < 0.05) (Fig-
ures 4A–B). TNF-α  enhanced significantly the percentage
of eosinophil adhesion to VCAM-1, ICAM-1 and IgG in
comparison to medium alone, by 177%, 205% and
169%, respectively. However, this effect was not inhibited
by dexamethasone (Figure 5).
Discussion
We have shown that dexamethasone inhibits the release
of IL-8 and GM-CSF in TNF-α  activated human peripheral
blood eosinophils from non-atopic volunteers.
The roles of GM-CSF and IL-8 in allergic inflammation are
well established. For example, GM-CSF is a potent survival
factor for eosinophils and IL-8 is an important chemoat-
tractant for neutrophils. The inhibitory effect of GCS on
the production of GM-CSF, IL-8 and MCP-1 by
Effect of dexamethasone on TNF-α -induced IL-8 and GM- CSF release from eosinophils Figure 4
Effect of dexamethasone on TNF-α -induced IL-8 and GM-
CSF release from eosinophils. Eosinophils were cultured with 
medium (control), or with TNF-α  (20 ng/ml) (TNF-α ) in the 
presence (Dexa) or absence (0) of dexamethasone (1 µM). 
IL-8 (A) and GM-CSF (B) release was evaluated by ELISA. 
Values are mean ± SEM (n = 5). *P < 0.05.
Effect of dexamethsone on TNF-α -induced eosinophil adhe- sion to VCAM-1 and ICAM-1 Figure 5
Effect of dexamethsone on TNF-α -induced eosinophil adhe-
sion to VCAM-1 and ICAM-1. Eosinophils were cultured in 
medium alone or with dexamethsone, or with TNF-α  (20 ng/
ml) or TNF-α  +dexamethsone in 96-wells plate coated with 
IgG, VCAM-1 and ICAM-1. EPO release was detected by 
colorimetric assay. Value are mean ± SEM (n = 3).Clinical and Molecular Allergy 2005, 3:5 http://www.clinicalmolecularallergy.com/content/3/1/5
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eosinophils after different stimuli has been demonstrated
[4]. However, its effect on eosinophils activated by TNF-α
has not been fully investigated as yet. In our system we
used dexamethasone to study the effect of GCS on TNF-α -
induced eosinophil activation. It is important to note that
different GCS have similar effects on inflammatory cells.
Several reports have demonstrated that the inhibition of
dexamethasone on eosinophil survival and activation par-
allels the one of inhaled GCS in vitro. For example, budes-
onide reduced the number of peripheral blood
eosinophils by suppressing both their progenitors in the
blood and colony-forming unit production in the bone
marrow [6,7]. It is also known that inhalation of high
doses of fluticasone reduced the number of blood eosi-
nophils by increasing their apoptosis in vivo [8].
Although dexamethasone has been shown to induce eosi-
nophil apoptosis, we have found that it did not decrease
eosinophil survival after 18 h of treatment. Therefore, its
effects on cytokine release observed in our system can not
be attributed to the eosinophil death. Dexamethasone, as
other GCS, inhibits cytokines release by eosinophils by
interference with transcription factors such as NF-kB and
AP-1 [9]. Since TNF-α  is a potent inducer of NF-kB in eosi-
nophils [10] we can hypothesize that dexamethasone
inhibits GM-CSF and IL-8 release in TNF-α  activated
eosinophils by blocking NF-kB (genomic mechanism). In
our study dexamethasone was unable to inhibit TNF-α -
induced ECP release and their adhesion to immobilised
VCAM-1, ICAM-1 and IgG. These data are in accordance
with previous works in which dexamethasone did not
affect the C5a- and IL-5 enhanced immunoglobulin-
induced eosinophil release of EDN [11].
Recent evidence supports a direct and extremely rapid
inhibitory effect of GCS on some activated inflammatory
cells (i.e. basophils) via a non-genomic effect that results
from the interaction of the GCS with biological mem-
branes [12]. However, we have not observed any effect of
dexamethasone on eosinophils degranulation and adhe-
sion (rapid events).
In conclusion, from our data we can speculate that GCS
exert beneficial effects in allergic inflammation also by
selectively inhibiting TNF-α -induced eosinophils release
of GM-CSF and IL-8, but not their survival, degranulation
and adhesion.
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